Comparing Nutriband (NTRB) & Its Rivals

Nutriband (NASDAQ:NTRB) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Nutriband to similar businesses based on the strength of its valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional and Insider Ownership

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Nutriband and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Nutriband Competitors	7750	13840	25675	1031	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.69%. Given Nutriband’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Nutriband has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Nutriband and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nutriband	$2.04 million	-$8.23 million	-12.53
Nutriband Competitors	$3.55 billion	$3.19 billion	545.58

Nutriband’s competitors have higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Nutriband and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Nutriband Competitors	-2,380.63%	-221.06%	-16.01%

Risk & Volatility

Nutriband has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Nutriband’s competitors have a beta of -4.81, indicating that their average stock price is 581% less volatile than the S&P 500.

Summary

Nutriband competitors beat Nutriband on 9 of the 13 factors compared.

Nutriband Company Profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.